Clinical Trial Readiness for the Evaluation and Treatment of Neuropsychiatric Manifestations in Tuberous Sclerosis Complex

$331,018U54FY2025NSNIH

Boston Children'S Hospital, Boston MA

Investigators

Linked publications & trials

Paper 39319594 Paper 39142021 Paper 38783199 Paper 38730350 Paper 38501559 Paper 38366765 Paper 38354030 Paper 38168271 Paper 38110041 Paper 37598571 Paper 37392087 Paper 37119787 Paper 37093598 Paper 36917158 Paper 36717037 Paper 36641436 Paper 36394118 Paper 36336205 Paper 36276299 Paper 35594551 Paper 35467831 Paper 35241692 Paper 35143913 Paper 34863106 Paper 34740315 Paper 34689816 Paper 34668231 Paper 34559195 Paper 34489750 Paper 34423884 Paper 34343869 Paper 34342000 Paper 34303785 Paper 33910615 Paper 33861989 Paper 33644493 Paper 33595755 Paper 33509259 Paper 33410532 Paper 33011641 Paper 32959437 Paper 32927206 Paper 32879655 Paper 32406614 Paper 32169041 Paper 32107139 Paper 32050889 Paper 32003824 Paper 31864941 Paper 31812987 Paper 31594918 Paper 31564436 Paper 31353853 Paper 31304656 Paper 31297797 Paper 31261349 Paper 31006514 Paper 31005478 Paper 30614812 Paper 30564771 Paper 30443929 Paper 30424962 Paper 30396833 Paper 30392627 Paper 30296632 Paper 30149055 Paper 30117265 Paper 30101418 Paper 29939236 Paper 29854952 Paper 29719671 Paper 29687739 Paper 29673547 Paper 29663862 Paper 29402632 Paper 29265961 Paper 29265708 Paper 29233840 Paper 29101226 Paper 28844798 Paper 28714064 Paper 28649286 Paper 28647006 Paper 28644979 Paper 28643795 Paper 28255759 Paper 27860216 Paper 27834639 Paper 27267556 Paper 27199644 Paper 27015721 Paper 26780584 Paper 26715604 Paper 26658953 Paper 26579216 Paper 26529580 Paper 26472761 Paper 26362832 Paper 26303409 Paper 26076992

Abstract

SUMMARY ABSTRACT: Neuropsychiatric and neurodevelopmental manifestations, including closely related autism spectrum disorder (ASD), intellectual disability (ID), and other neurobehavioral difficulties, are prominent in the majority of patients with Tuberous Sclerosis Complex (TSC). Collectively, the intertwined constellation of these cognitive, neurobehavioral deficits, including sleep and sensory impairments, is referred to as TSC-associated neuropsychiatric disorders (TAND). There is a lack of TAND-specific treatments studied for use in TSC. The Developmental Synaptopathies Consortium (DSC) seeks to address this need by addressing critical gaps in clinical trial readiness for developing potential therapies (pharmacological and non-pharmacological) for TAND in TSC. Over the last five years, this has included development of the self-administered and quantified version of the TAND Checklist (TAND-SQ) in collaboration with the TANDem consortium and piloted work on novel electrophysiological biomarkers for ASD and ID in TSC. Over the next five years, we plan to validate the TAND- SQ for use in future clinical trials (AIM 1). We also will conduct the first prospective longitudinal assessment of psychiatric conditions and mental health symptoms in TSC, along with establishing the landscape of psychotropic medication use, in TSC patients with TAND (AIM 2). Finally, we will newly characterize sleep difficulties and abnormalities in sensory processing within the TAND phenotype and further develop corresponding electrophysiological biomarkers of each as potential measures of abnormal neuronal circuitry contributing to the pathobiology of TAND in TSC and their potential suitability for use in future clinical trials (AIM 3). The proposed research will also improve our understanding of the neurobiology of neurodevelopmental disorders such as ASD and ID and aid in developing treatments for these disorders more broadly.

View original record on NIH RePORTER →